Table 1. Characteristics of identified studies.
Key results/Findings (psychometric properties) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Author (s) | Country | Year | Sample Size | Source | PWB α | EWB α | FGWB α | SWB α | CF α | FAHI | Established | Sensitivity | |
Total α | validity | to change | |||||||||||
Byrne S. & Petry N. [30] | USA | 2012 | n = 170 | Single | 0.85 | 0.89 | 0.82 | 0.70 | 0.70 | 0.92 | Convergent | YES | |
Discriminant | |||||||||||||
Peterman A.H. et al [22] | USA | 1997 | n = 361 | BIOQoL (n = 110) | Divergent | YES | |||||||
VCU data (n = 39) | 0.91 | 0.82 | 0.86 | 0.73 | 0.75 | 0.91 | Construct | ||||||
Multi-center trial (n = 212) | |||||||||||||
Viala-Danten M. et al [13] | USA | 2010 | n = 1661 | POWER trial (n = 565) | 0.91 | 0.83 | 0.89 | 0.85 | 0.75 | NR | Construct | NR | |
DUET trial (n = 1,091*) | 0.92 | 0.84 | 0.89 | 0.84 | 0.72 | NR | |||||||
Cella D.F. et al [17] | USA | 1996 | n = 245 | Stress sample (n = 110) | 0.91 | Concurrent | YES | ||||||
BIOQoL English (n = 71) | NR | NR | NR | NR | NR | 0.91 | |||||||
BIOQoL Spanish (n = 64) | 0.92 | ||||||||||||
Feinberg J. et al [34] | USA, Canada | 2011 | n = 429 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
& Puerto Rico | |||||||||||||
Earthman C.P. [33] | USA | 2002 | n = 25 | Single | 0.91 (7 Item) | NR | NR | NR | NR | NR | NR | NR | |
Hasanah C.I., Zaliha A.R., | Malaysia | 2010 | n = 271 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
Mahiran M. [23] | |||||||||||||
Cianfrocca M. et al [35] | USA | 2010 | n = 73 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
Rao D. et al [24] | Continental | 2007 | n = 273 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
United States | |||||||||||||
& Puerto rico | |||||||||||||
Abrams D.I, Steinhart C., | USA | 2000 | n = 221 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
Frascino R. [36] | |||||||||||||
Tomita A et al [31] | South Africa | 2013 | n = 160 | Single | 0.88 | 0.83 | 0.85 | 0.72 | 0.65 | 0.86 | NR | NR | |
Tomita A et al [37] | South Africa | 2014 | n = 51 | Single | 0.92 | 0.80 | 0.83 | 0.73 | 0.60 | 0.90 | NR | NR | |
Diamond C., | USA | 2010 | n = 100 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
Taylor T.H., | |||||||||||||
Anton-Culver H. [38] | |||||||||||||
Cella D.F. et al [39] | USA | 2010 | n = 1203 | DUET– 1 (n = 612) | NR | NR | NR | NR | NR | NR | NR | NR | |
DUET– 2 (n = 591) | |||||||||||||
Sikkema K.J. et al [40] | USA | 2005 | n = 235 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
Winston A. [41] | Multi- centered | 2010 | n = 256 | Single | NR | NR | NR | NR | NR | NR | NR | NR |
BIOQoL-Bilingual Intercultural Oncology Quality of Life, VCU -Virginia Commonwealth University, FAHI–Functional Assessment of HIV infection, PWB–Physical Wellbeing, EWB–Emotional Wellbeing, FWB–Functional and Global Wellbeing, SWB–Social Wellbeing, CF–Cognitive Functioning, POWER–Performance Of TMC114/r When evaluated in treatment-Experienced patients with protease inhibitor Resistance. DUET- a randomized, double-blind, placebo-controlled, phase III trial examining the efficacy, tolerability, and safety of TMC125 in treatment-experienced patients. NR–Not Reported
* Number of patients with all sub scale scores available